(Pictured Above: ProxsysRx VP and 340B team leader Heather Brooks)
It’s no secret that manufacturer drug restrictions have devastated the 340B programs of countless covered entities. And yet, since 2019, ProxsysRx has generated more than $500 million in 340B revenues for the health systems we serve. Savings and revenue which, for many of those health systems, literally means the difference between solvency and closure.
The positive impact of those recovered revenues has been profound. As the Director of Pharmacy of one health system put it, in a conversation published on our blog, “It’s allowed us to expand into areas of medicine we never thought we could offer. We’ve added a cancer center, a pain clinic as part of our orthopedic practice, a dermatology clinic, and a women’s center. We’re expanding our footprint, and we’re treating so many more patients than we used-to. Without ProxsysRx and 340B, that wouldn’t have been possible.”
Learn how your health system can overcome manufacturer restrictions
To schedule a meet-up during the 2024 HFMA Conference, contact Howard Hall C: 214.808.2700 | howard.hall@proxsysrx.com. Or Click Here to access Howard’s schedule.
